AIDS vaccine may be far off.

AIDS vaccine may be far off, but route to it really is getting clearer In his latest Washington Post opinion piece, columnist Michael Gerson highlights scientific efforts to create an AIDS vaccine, noting the ongoing work of researchers at the Vaccine Research Middle. ‘In the short and medium terms, neither injected antibodies nor a vaccine will be a substitute for other forms of AIDS prevention. But experts at NIH know that an effective vaccine would be a decisive defeat because of their wily enemy,’ he writes. ‘Your day that work is finished remains distant. But now, at least, there is a way to the moon,’ Gerson concludes . This article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family members Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family members Foundation, a nonpartisan healthcare policy research business unaffiliated with Kaiser Permanente.In pre-scientific reference models of HIV, ABX464 has proven its unique capability to induce a considerable reduction in viral load that persists for weeks after treatment arrest. This anti-viral effect hasn’t been noticed with existing treatments. With current HIV remedies, the virus begins multiplying as soon as the drugs are withdrawn again, which means daily typically, life-long treatment for individuals. Additionally, in pre-clinical testing, the HIV virus did not develop any level of resistance to ABX464. Pending confirmation in medical trials, this unique mode of action and preclinical data to-date suggest that ABX464 could: Induce long term control of the viral load Not really induce HIV mutants that are resistant to treatment Be less administered over a shorter period than standard remedies frequently; providing the potential to reduce healthcare costs and offer broader usage of treatment Having reviewed the entire current data bundle for ABX464, Professor Mark Wainberg, M.D., previous President of the International Helps Society and among the top HIV professionals worldwide, summarized his perspective on this novel candidate drug by saying: If these unique top features of ABX464 are confirmed in the medical development program in HIV patients that’s now underway, ABX464 could become the central component of a functional cure for Helps.